Sunday, October 25, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 6, 2026

The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson

View original at finance.yahoo.com
“Eli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference

    80% confidence
  • Eli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year

    80% confidence
  • Intuitive Surgical has an expected revenue and earnings growth rate of 14.3% and 11.1%, respectively, for the current year

    80% confidence
  • Johnson & Johnson carries a Zacks Rank #3 (Hold)

    80% confidence
  • REGN has an ROE of 13.8% compared with the industry's ROE of -65.41% and the S&P 500's ROE of 17%

    80% confidence
  • Regeneron Pharmaceuticals has an expected revenue and earnings growth rate of 4.9% and -0.4%, respectively, for the current year

    80% confidence
  • Johnson & Johnson carries a Zacks Rank #3 (Hold)

    80% confidence
  • Eli Lilly currently sports a Zacks Rank #1 (Strong Buy)

    80% confidence
  • Hypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity

    80% confidence
  • ISRG has an ROE of 15.1% compared with the industry's ROE of -18.7% and the S&P 500's ROE of 17%

    80% confidence
  • Intuitive Surgical has an expected earnings growth rate of 11.1% for the current year

    80% confidence
  • Eli Lilly has an expected revenue growth rate of 22.3% for the current year

    80% confidence
  • Intuitive Surgical has an expected revenue growth rate of 14.3% for the current year

    80% confidence
  • The Zacks Consensus Estimate for Eli Lilly current-year earnings has improved 0.7% over the last 30 days

    80% confidence
  • AI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency

    80% confidence
  • Regeneron Pharmaceuticals carries a Zacks Rank #2 (Buy)

    80% confidence
  • Hypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity

    80% confidence
  • Medtronic has an expected revenue growth rate of 7.5% for the current year (ending April 2026)

    80% confidence
  • Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to S&P 500's +7.7% average gain per year

    80% confidence
  • Johnson & Johnson has an expected revenue growth rate of 5% for the current year

    80% confidence
  • The healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers

    80% confidence
  • JNJ has an ROE of 32.7% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%

    80% confidence
  • Regeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year

    80% confidence
  • The supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.

    80% confidence
  • MDT has an ROE of 14.9% compared with the industry's ROE of -2.5% and the S&P 500's ROE of 17%

    80% confidence
  • Eli Lilly has a return on equity of 109.5% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%

    80% confidence
  • The medical sector is one of the major adopters of artificial intelligence, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster as well as more accurate diagnosis

    80% confidence
  • Medtronic has an expected earnings growth rate of 2.7% for the current year (ending April 2026)

    80% confidence
  • Zacks top stock-picking strategies soared with average gains of +48.4%, +50.2% and +56.7% per year since 2000

    80% confidence
  • Eli Lilly has an expected earnings growth rate of 41.3% for the current year

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson — Source | Via News | ViaNews Market